Zacks Investment Research upgraded shares of Tocagen (NASDAQ:TOCA) from a sell rating to a hold rating in a research note issued to investors on Thursday, January 11th.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
Shares of Tocagen (TOCA) traded down $0.21 during trading on Thursday, reaching $12.12. The company had a trading volume of 95,600 shares, compared to its average volume of 170,427. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03. Tocagen has a 1 year low of $8.60 and a 1 year high of $17.95.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. equities research analysts anticipate that Tocagen will post -2.66 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new position in Tocagen in the second quarter valued at approximately $108,000. Schwab Charles Investment Management Inc. acquired a new position in Tocagen in the second quarter valued at approximately $165,000. BBR Partners LLC acquired a new position in shares of Tocagen during the third quarter worth approximately $181,000. California State Teachers Retirement System acquired a new position in shares of Tocagen during the second quarter worth approximately $179,000. Finally, Teachers Advisors LLC acquired a new position in shares of Tocagen during the second quarter worth approximately $181,000. Institutional investors own 36.22% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Tocagen (NASDAQ:TOCA) Upgraded at Zacks Investment Research” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/18/tocagen-toca-upgraded-by-zacks-investment-research-to-hold.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Get a free copy of the Zacks research report on Tocagen (TOCA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.